No association between the TP53 codon 72 polymorphism and risk or prognosis of Hodgkin and non-Hodgkin lymphoma

Leukemia Research

Volumn 35, Issue 8, 2011, Pages 1117-1119

  Havranek, Ondrej ^a   Spacek, Martin ^b   Hubacek, Petr ^c   Mocikova, Heidi ^b   Benesova, Katerina ^a   Soucek, Pavel ^d   Trneny, Marek ^a   Kleibl, Zdenek ^b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^d NATIONAL INSTITUTE OF PUBLIC HEALTH   (Czech Republic)

Author keywords

Arg72Pro polymorphism (R72P); Genetic predisposition; Hodgkin lymphoma; Non Hodgkin lymphoma; Prognosis; TP53 gene (p53)

Indexed keywords

GENOMIC DNA; PROTEIN P53;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CAUCASIAN; CODON; CONTROLLED STUDY; FEMALE; FOLLICULAR LYMPHOMA; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENOTYPE; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MUTATION RATE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CODON; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HODGKIN DISEASE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROGNOSIS; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 79960266041     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.04.001     Document Type: Article

References (13)

1. Vousden K.H., Lane D.P. p53 in health and disease. Nat Rev Mol Cell Biol 2007, 8:275-283.
2. Palmero E.I., Achatz M.I., Ashton-Prolla P., Olivier M., Hainaut P. Tumor protein 53 mutations and inherited cancer: beyond Li-Fraumeni syndrome. Curr Opin Oncol 2010, 22:64-69.
3. Cheung K.J., Horsman D.E., Gascoyne R.D. The significance of TP53 in lymphoid malignancies: mutation prevalence, regulation, prognostic impact and potential as a therapeutic target. Br J Haematol 2009, 146:257-269.
4. Francisco G, Menezes PR, Eluf-Neto J, Chammas R. Arg72Pro TP53 polymorphism and cancer susceptibility: A comprehensive meta-analysis of 302 case-control studies. Int J Cancer, doi:10.1002/ijc.25710.
5. Hishida A., Matsuo K., Tajima K., Ogura M., Kagami Y., Taji H., et al. Polymorphisms of p53 Arg72Pro, p73 G4C14-to-A4T14 at exon 2 and p21 Ser31Arg and the risk of non-Hodgkin's lymphoma in Japanese. Leuk Lymphoma 2004, 45:957-964.
6. Kim H.N., Yu L., Kim N.Y., Lee I.K., Kim Y.K., Yang D.H., et al. Association with TP53 codon 72 polymorphism and the risk of non-Hodgkin lymphoma. Am J Hematol 2010, 85:822-824.
7. Bittenbring J., Parisot F., Wabo A., Mueller M., Kerschenmeyer L., Kreuz M., et al. MDM2 gene SNP309T/G and p53 gene SNP72 G/C do not influence diffuse large B-cell non-Hodgkin lymphoma onset or survival in central European Caucasians. BMC Cancer 2008, 8:116.
8. Morton L.M., Purdue M.P., Zheng T., Wang S.S., Armstrong B., Zhang Y., et al. Risk of non-Hodgkin lymphoma associated with germline variation in genes that regulate the cell cycle, apoptosis, and lymphocyte development. Cancer Epidemiol Biomarkers Prev 2009, 18:1259-1270.
9. Hill D.A., Wang S.S., Cerhan J.R., Davis S., Cozen W., Severson R.K., et al. Risk of non-Hodgkin lymphoma (NHL) in relation to germline variation in DNA repair and related genes. Blood 2006, 108:3161-3167.
10. Wrench D., Waters R., Carlotti E., Iqbal S., Matthews J., Calaminici M., et al. Clinical relevance of MDM2 SNP 309 and TP53 Arg72Pro in follicular lymphoma. Haematologica 2009, 94:148-150.
11. Wang S.S., Maurer M.J., Morton L.M., Habermann T.M., Davis S., Cozen W., et al. Polymorphisms in DNA repair and one-carbon metabolism genes and overall survival in diffuse large B-cell lymphoma and follicular lymphoma. Leukemia 2009, 23:596-602.
12. Kleibl Z., Havranek O., Hlavata I., Novotny J., Sevcik J., Pohlreich P., Soucek P. The CHEK2 gene I157T mutation and other alterations in its proximity increase the risk of sporadic colorectal cancer in the Czech population. Eur J Cancer 2009, 45:618-624.
13. Young K.H., Leroy K., Moller M.B., Colleoni G.W., Sanchez-Beato M., Kerbauy F.R., et al. Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. Blood 2008, 112:3088-3098.